- Home
- TEI vs ABEO Comparison
TEI vs ABEO Comparison
Compare TEI & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEI
- ABEO
- Stock Information
- Founded
- TEI 1993
- ABEO 1974
- Country
- TEI United States
- ABEO United States
- Employees
- TEI N/A
- ABEO N/A
- Industry
- TEI Finance Companies
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- TEI Finance
- ABEO Health Care
- Exchange
- TEI Nasdaq
- ABEO Nasdaq
- Market Cap
- TEI 282.9M
- ABEO 281.0M
- IPO Year
- TEI N/A
- ABEO 1980
- Fundamental
- Price
- TEI $6.28
- ABEO $4.57
- Analyst Decision
- TEI
- ABEO Strong Buy
- Analyst Count
- TEI 0
- ABEO 5
- Target Price
- TEI N/A
- ABEO $18.20
- AVG Volume (30 Days)
- TEI 142.4K
- ABEO 2.9M
- Earning Date
- TEI 01-01-0001
- ABEO 11-12-2025
- Dividend Yield
- TEI 10.51%
- ABEO N/A
- EPS Growth
- TEI N/A
- ABEO N/A
- EPS
- TEI N/A
- ABEO 1.29
- Revenue
- TEI N/A
- ABEO $400,000.00
- Revenue This Year
- TEI N/A
- ABEO N/A
- Revenue Next Year
- TEI N/A
- ABEO $324.71
- P/E Ratio
- TEI N/A
- ABEO $3.54
- Revenue Growth
- TEI N/A
- ABEO N/A
- 52 Week Low
- TEI $4.35
- ABEO $3.93
- 52 Week High
- TEI $5.39
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- TEI 44.27
- ABEO 45.80
- Support Level
- TEI $6.27
- ABEO $4.37
- Resistance Level
- TEI $6.50
- ABEO $4.63
- Average True Range (ATR)
- TEI 0.08
- ABEO 0.32
- MACD
- TEI -0.02
- ABEO 0.04
- Stochastic Oscillator
- TEI 5.98
- ABEO 35.08
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.